Highlights
- •We report two cases of ipilimumab-induced meningoradiculitis.
- •Neurological immune-related adverse events (irAES) with anti CTLA4 are uncommon.
- •A prompt diagnosis of irAES is necessary to start a suitable treatment as soon as possible.
- •Corticosteroids should be considered as the first-line treatment for all neurological irAEs.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical NeuroscienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010; 363: 711-723
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.Eur J Cancer. 2017; 73: 1-8
- Neurological toxicities associated with immune-checkpoint inhibitors.Curr Opin Neurol. 2017; 30: 659-668
- Severe meningo-radiculo-neuritis associated with ipilimumab.Invest New Drugs. 2012; 30: 2407-2410
- Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.Muscle Nerve. 2013; 48: 440-444
- Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy.Eur J Cancer. 2017; 83: 28-31
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2018; 29: 264-266
Article info
Publication history
Published online: December 28, 2018
Accepted:
December 11,
2018
Received:
November 2,
2018
Identification
Copyright
© 2018 Elsevier Ltd. All rights reserved.
